---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-242912"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:19:08.333389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M

## Summary
- Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.
- No dose-limiting toxicities, treatment-related discontinuations, or Grade 4/5 adverse events observed across 55 treated patients.
- 14 of 16 Cohort 2 patients with SSTR2+ all tumors remain progression-free and on study (87.5%).
- Preliminary cash, cash equivalents and short-term investments ~$174.1M as of Sep 30, 2025, funding operations into late 2026.
- Initial efficacy data for additional 31 patients expected in 2026; company plans registration study based on emerging profile.

## SEC filing metadata
- accession: 0001193125-25-242912
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/0001193125-25-242912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312525242912/catx-20251020.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-242912
- JSON: https://secwatch.observer/filing/0001193125-25-242912.json
- Plain text: https://secwatch.observer/filing/0001193125-25-242912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.